Noticias y eventos de KALA BIO Inc (KALA)KALAKALA BIO Inc

Kala Bio and Virotek Finalize Exclusive Distribution Agreement

Kala Bio and Virotek announced that they have finalized a definitive exclusive distribution and reseller agreement and related quality, brand, and data protection agreements. Under the agreement, Kala will be the exclusive distributor and reseller in the United States for an initial one-year term, with continued exclusivity contingent on Kala achieving agreed commercial milestones for Virotek's ophthalmology genetic testing and screening program. The agreement follows the non-binding letter of intent announced by the companies on September 1 and takes effect on September 4. Under the agreement, Kala holds the exclusive right to market, promote, distribute, and resell Virotek's ophthalmology genomic program throughout the United States for an initial one-year term, with exclusivity contingent on Kala achieving agreed commercial milestones. Virotek continues to operate the program's infrastructure, kit supply, specimen processing, and clinical reporting, and will provide training and program materials to Kala's channel partners. The companies have agreed to a profit-sharing structure for the program, effective once Virotek recovers its program costs. This release does not set out additional commercial and financial terms of the agreement. The agreement also includes a right of first refusal in favor of Kala for certain ophthalmology products and services that Virotek may propose to sell or license to a third party. It also establishes a framework under which the companies may, by mutual agreement, activate additional clinical verticals over time, including oncology, a preventive-health testing franchise, telehealth, and white-label distribution channels.

Kala Bio and Virotek Sign LOI to Exclusively Distribute Genetic Testing

Kala Bio and Virotek announced that they have entered into a letter of intent outlining the principal terms under which the companies intend to negotiate a definitive agreement appointing Kala as the exclusive distributor and reseller in the United States of Virotek's genetic testing and screening program for ophthalmological indications. Under the framework outlined in the LOI, Kala would market, promote, and distribute Virotek's ophthalmology genetic testing and screening program to eye care practices, telehealth platforms, and other channels across the United States, while Virotek continues to operate the program's underlying CLIA-registered laboratory infrastructure, kit fulfillment, specimen processing, and clinical reporting. The companies have also outlined a framework under which the collaboration could, by mutual agreement, expand over time into additional clinical verticals, including oncology and a preventive-health testing franchise, as well as telehealth and white-label channels. The proposed partnership extends a therapeutic area Kala already knows well. Kala Bio Inc., formerly Kala Pharmaceuticals, built and commercialized two FDA-approved ophthalmic therapies before divesting that commercial franchise to Alcon in 2022. Kala's clinical-stage pipeline remains centred on the eye. Virotek's ophthalmology genetic testing and screening program gives Kala a commercial, revenue-generating opportunity in the same clinical area the company has been built around, alongside Kala's existing relationships across the U.S. eye care community. The LOI and the proposed transaction remain subject to, among other things, the negotiation and execution of definitive agreements, and other customary conditions, including required corporate, regulatory, and Nasdaq approvals. The companies are targeting execution of definitive agreements within approximately 30 days of signing the LOI, although there can be no assurance that definitive agreements will be reached on these or any terms, or at all.

Kala Bio Shares Drop 21.7% to $3.06

Kala Bio is down -21.7%, or -85c to $3.06.